Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is thrilled to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application number 16/076,026.
This new patent will provide Enlivex with added intellectual property protection for its Allocetra™ immunotherapy through 2036, enabling it to be used in combination with chimeric antigen receptor (CAR) T-cell therapy to treat, ameliorate or allveiate tumors. The Company expects that this patent will be issued in the United States during 2023.
Allocetra™ is an innovative, cutting-edge cell therapy designed to restore macrophage homeostasis, a crucial component of the body’s immune system.
By tackling diseases such as solid cancers, sepsis, and many others that reprogram macrophages out of their homeostatic state, Allocetra™ has the potential to provide a powerful, novel immunotherapeutic mechanism of action for life-threatening conditions that are defined as “unmet medical needs”.
This versatile, off-the-shelf cell therapy could be used as a stand-alone treatment or in combination with existing therapeutic agents.
Enlivex, a clinical stage macrophage reprogramming immunotherapy company, is developing Allocetra™ – a revolutionary, universal off-the-shelf cell therapy designed to reprogram macrophages and reset them into their homeostatic state. This groundbreaking therapy has the potential to rebalance the immune system and resolve life-threatening conditions.